T. Rowe Price Associates
ARCT icon

T. Rowe Price Associates’s Arcturus Therapeutics ARCT Stock Holding History

T. Rowe Price Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
36,887
+7,094
+24% +$55.9K ﹤0.01% 2925
2026
Q1 		$231K Buy
29,793
+3,679
+14% +$26.8K ﹤0.01% 2789
2025
Q4 		$161K Sell
26,114
-1,838
-7% -$19.9K ﹤0.01% 2858
2025
Q3 		$516K Buy
27,952
+4,679
+20% +$75.2K ﹤0.01% 2341
2025
Q2 		$303K Buy
23,273
+3,152
+16% +$37.3K ﹤0.01% 2521
2025
Q1 		$214K Buy
20,121
+1,103
+6% +$17.5K ﹤0.01% 2599
2024
Q4 		$323K Buy
19,018
+1,279
+7% +$24.1K ﹤0.01% 2478
2024
Q3 		$412K Buy
17,739
+122
+0.7% +$2.61K ﹤0.01% 2335
2024
Q2 		$429K Buy
17,617
+613
+4% +$18.6K ﹤0.01% 2249
2024
Q1 		$575K Buy
17,004
+922
+6% +$32.7K ﹤0.01% 2154
2023
Q4 		$508K Buy
16,082
+360
+2% +$8.56K ﹤0.01% 2162
2023
Q3 		$402K Sell
15,722
-3,535
-18% -$109K ﹤0.01% 2215
2023
Q2 		$553K Sell
19,257
-617
-3% -$16.8K ﹤0.01% 2078
2023
Q1 		$477K Buy
19,874
+105
+0.5% +$1.88K ﹤0.01% 2127
2022
Q4 		$335K Buy
19,769
+1,522
+8% +$26.5K ﹤0.01% 2328
2022
Q3 		$271K Buy
18,247
+1,515
+9% +$25.4K ﹤0.01% 2422
2022
Q2 		$263K Buy
16,732
+410
+3% +$8.05K ﹤0.01% 2496
2022
Q1 		$440K Buy
16,322
+1,283
+9% +$32.7K ﹤0.01% 2393
2021
Q4 		$557K Buy
15,039
+298
+2% +$12.1K ﹤0.01% 2335
2021
Q3 		$704K Sell
14,741
-119,000
-89% -$5.33M ﹤0.01% 2213
2021
Q2 		$4.53M Sell
133,741
-49,328
-27% -$1.67M ﹤0.01% 1522
2021
Q1 		$7.56M Sell
183,069
-1,239,110
-87% -$73.9M ﹤0.01% 1426
2020
Q4 		$61.7M Buy
1,422,179
+718,793
+102% +$48.7M 0.01% 882
2020
Q3 		$30.2M Buy
703,386
+185,549
+36% +$9.21M ﹤0.01% 1037
2020
Q2 		$24.2M Buy
+517,837
New +$17.8M ﹤0.01% 1095

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

T. Rowe Price Associates's ARCT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Arcturus Therapeutics (ARCT) stake by 24% in Q2 2026, buying an estimated $55.9K and bringing the position to 36,887 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

T. Rowe Price Associates first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $61.7M in Q4 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • T. Rowe Price Associates held 36,887 shares of Arcturus Therapeutics worth $248K as of Q2 2026.
  • T. Rowe Price Associates bought 7,094 Arcturus Therapeutics shares in Q2 2026, an estimated $55.9K.
  • Arcturus Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2925 holding.
  • T. Rowe Price Associates first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • T. Rowe Price Associates's Arcturus Therapeutics position peaked at $61.7M in Q4 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.